Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass
- 21 December 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 100 (25) , 2499-2506
- https://doi.org/10.1161/01.cir.100.25.2499
Abstract
Background—Cardiopulmonary bypass (CPB) induces a systemic inflammatory response that causes substantial clinical morbidity. Activation of complement during CPB contributes significantly to this in...Keywords
This publication has 47 references indexed in Scilit:
- Cognitive Outcome After Coronary Artery Bypass: A One-Year Prospective StudyThe Annals of Thoracic Surgery, 1997
- Inhibition of complement activity by humanized anti-C5 antibody and single-chain FvMolecular Immunology, 1996
- Current incidence and determinants of perioperative myocardial infarction in coronary artery surgeryAmerican Heart Journal, 1996
- Selection and clinical significance of neuropsychologic testsThe Annals of Thoracic Surgery, 1995
- Microemboli during coronary artery bypass grafting: Genesis and effect on outcomeThe Journal of Thoracic and Cardiovascular Surgery, 1995
- Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenatorsThe Annals of Thoracic Surgery, 1993
- Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5).The Journal of Experimental Medicine, 1988
- Effects of coronary artery revascularization and perioperative myocardial infarction on left ventricular wall motionInternational Journal of Cardiology, 1987
- Changes in Left Ventricular Performance Related to Perioperative Myocardial Infarction in Coronary Artery Bypass Graft SurgeryThe Annals of Thoracic Surgery, 1983
- Complement Activation during Cardiopulmonary BypassNew England Journal of Medicine, 1981